AbbVie Inc. (SNSE:ABBVCL)

Market Cap	368.77T
Revenue (ttm)	57.35T
Net Income (ttm)	2.26T
Shares Out	n/a
EPS (ttm)	1,269.91
PE Ratio	163.33
Forward PE	16.52
Dividend	6,400.30 (3.73%)
Ex-Dividend Date	Oct 15, 2025

Volume	n/a
Average Volume	0
Open	n/a
Previous Close	171,590
Day's Range	n/a
52-Week Range	161,963 - 219,480
Beta	n/a
RSI	29.67
Earnings Date	Jan 30, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Santiago Stock Exchange
• Ticker Symbol: ABBVCL

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD